<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085366</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1647-P301</org_study_id>
    <secondary_id>2020-006051-17</secondary_id>
    <nct_id>NCT05085366</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age</brief_title>
  <official_title>A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in&#xD;
      CMV-seronegative female participants and to evaluate the safety and reactogenicity of&#xD;
      mRNA-1647 vaccine in all participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2021</start_date>
  <completion_date type="Anticipated">July 29, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Observer-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion From a Negative to a Positive Result for Serum Immunoglobulin G (IgG) Against Antigens not Encoded by mRNA-1647</measure>
    <time_frame>Day 197 (28 days after the third injection) up to Day 887 (24 months after the third injection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Adverse Reactions (ARs)</measure>
    <time_frame>Up to 176 days (7 days after each injection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Up to 197 days (28 days after each injection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Medically-Attended Adverse Events (MAAEs)</measure>
    <time_frame>Day 1 through 6 months after the last injection (up to 347 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Event of Special Interests (AESIs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 through end of study (up to Day 887)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Antigen-Specific Neutralizing Antibody (nAb) and Binding Antibody</measure>
    <time_frame>Day 1, Months 3, 7, 12, 18, 24, and 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6900</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>mRNA-1647</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mRNA-1647 vaccine by intramuscular (IM) injection on Day 1, Day 57, and Day 169.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive mRNA-1647 vaccine matching placebo by IM injection on Day 1, Day 57, and Day 169.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1647</intervention_name>
    <description>Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline)</description>
    <arm_group_label>mRNA-1647</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride (normal saline) injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Participants aged ≥20 years, has or anticipates having direct exposure (in the home,&#xD;
             socially, or occupationally) to at least 1 child ≤5 years of age. Direct exposure is&#xD;
             defined as either participant is the parent, or participant has close contact&#xD;
             (feeding, diaper changes, childcare/supervision) for at least 8 hours per week.&#xD;
&#xD;
          -  CMV-seronegative Cohort is CMV-seronegative based on CMV testing at Screening.&#xD;
&#xD;
          -  CMV-seropositive Cohort is CMV-seropositive based on CMV testing at Screening.&#xD;
&#xD;
          -  Investigator assessment confirms that the participant (including in the case of an&#xD;
             emancipated minor), or parent(s)/legally acceptable representative (LAR)(s), as&#xD;
             applicable, understand and are willing and physically able to comply with&#xD;
             protocol-mandated follow-up including all study visits and procedures anticipated&#xD;
             during the 30 month study period.&#xD;
&#xD;
          -  Has a body mass index of 15-35 kilograms (kg)/square meter (m^2), inclusive.&#xD;
&#xD;
          -  Female participants: Urine pregnancy test is negative at Screening and negative on the&#xD;
             day of the first injection (Day 1). If the participant is sexually active, has&#xD;
             practiced adequate contraception for at least 28 days prior to the first injection&#xD;
             (Day 1) and agrees to continue adequate contraception through 3 months following the&#xD;
             third study injection (Month 9/Day 257).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Female participant is of non-childbearing potential.&#xD;
&#xD;
          -  History of a diagnosis or condition that, in the judgment of the Investigator, is&#xD;
             clinically unstable or may affect participant safety, assessment of safety endpoints,&#xD;
             assessment of immune response, or adherence to study procedures.&#xD;
&#xD;
          -  Received or plans to receive any nonstudy vaccine &lt;28 days prior to any study&#xD;
             injection; in addition, the following criteria for COVID-19 and influenza vaccines&#xD;
             apply:&#xD;
&#xD;
          -  Any Coronavirus disease 2019 (COVID-19) vaccination series must have been completed a&#xD;
             minimum 28 days prior to receiving any dose of the study injection.&#xD;
&#xD;
          -  COVID-19 vaccines (regardless of manufacturer) must be administered at least 28 days&#xD;
             prior to or after any study injection.&#xD;
&#xD;
          -  Influenza vaccines may be administered &gt; 14 days prior to or after any study&#xD;
             injection.&#xD;
&#xD;
          -  Received systemic immunosuppressants or immune-modifying drugs for &gt;14 days in total&#xD;
             within 6 months prior to the day of first injection (Day 1) (for corticosteroids, ≥5&#xD;
             milligrams (mg)/day of prednisone equivalent) or plans to do so during the course of&#xD;
             the study. Inhaled, nasal, and topical steroids are allowed.&#xD;
&#xD;
          -  Receipt of an antiviral with activity against CMV (ganciclovir, valganciclovir,&#xD;
             foscarnet, cidofovir, letermovir, acyclovir, valacyclovir) &lt;2 weeks prior to the day&#xD;
             of first injection or plans to do so during the course of the study.&#xD;
&#xD;
          -  Previous receipt of an investigational CMV vaccine.&#xD;
&#xD;
          -  Receipt of systemic immunoglobulins or blood products &lt;3 months prior to the day of&#xD;
             first injection.&#xD;
&#xD;
          -  Participated in an interventional clinical study &lt;28 days prior to the day of first&#xD;
             injection (Day 1) or plans to do so while enrolled in this study.&#xD;
&#xD;
          -  Participant has donated ≥450 milliliters (mL) of blood products &lt;28 days prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Participant is a member of study team or is an immediate family member or household&#xD;
             member of study personnel.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cahaba Research, Inc. - Pelham</name>
      <address>
        <city>Pelham</city>
        <state>Alabama</state>
        <zip>35124-6300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015-1105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research, LLC - Hunt</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Banning</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Chula Vista</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911-6617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research Institute, Inc.</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942-3189</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - San Diego</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research Institute, Inc. - ClinEdge</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001-0172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of The Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>32132-2720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants LLC</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460-4647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132-2720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research, LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281-9054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johnson Country Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates - Newton</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006-4151</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Rockville Maryland)</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854-2957</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC - Albuquerque</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MediSync Clinical Research Hattiesburg Clinic</name>
      <address>
        <city>Petal</city>
        <state>Mississippi</state>
        <zip>39465-2932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Grand Island, Nebraska)</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803-4327</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Hastings, Nebraska)</name>
      <address>
        <city>Hastings</city>
        <state>Nebraska</state>
        <zip>68901-2615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Norfolk-Nebraska)</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701-2669</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-3755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Omaha Nebraska)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102-3644</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901-1046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC - ClinEdge</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277-4442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2975</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinOhio Research Services</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213-4440</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research - Oklahoma - Platinum</name>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <zip>73099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARC Clinical Research at Wilson Parke</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78726-4061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARC Clinical Research at William Cannon</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research - Beaumont</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77706-3061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Austin</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613-3936</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic - South Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Boise</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads Inc. - ClinEdge</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>York Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510-2014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225-4017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-1647</keyword>
  <keyword>Moderna</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <keyword>Cytomegalovirus Vaccine</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Cytomegalovirus Congenital</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Infection Viral</keyword>
  <keyword>DNA Virus Infections</keyword>
  <keyword>Messenger RNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

